Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk
Danielle Gilliam, Executive Medical Science Liaison Cardiovascular and Renal at Novo Nordisk North America, shared on LinkedIn:
”The FDA’s approval also clears the pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease, according to Novo Nordisk.”
Find more here.
Read the full announcement by Novo Nordisk here.
Novo Nordisk announced that the US Food and Drug Administration has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, for long-term weight reduction and maintenance, as well as for reducing the risk of major adverse cardiovascular events.
The oral formulation is indicated for adults with obesity or overweight who have at least one weight-related comorbidity, and for adults with established heart disease to lower the risk of death, heart attack, or stroke.
In addition, Wegovy injection is approved for chronic weight management in paediatric patients aged 12 years and older.
The injectable form is also approved for the treatment of MASH in adults with moderate to advanced liver fibrosis, excluding those with cirrhosis.
Stay updated with Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly